CRISPR NEWS

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology” September 10, 2018

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Court of Appeals for the Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR-Cas9 Genome Editing Technology

On September 10, 2018 the U.S. Court of Appeals for the Federal Circuit affirmed the decision by the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board in an interference proceeding relating to CRISPR-Cas9 genome editing technology. The interference was requested by CVC, co-owners of foundational intellectual property relating to CRISPR/Cas9 genome engineering, against the Broad Institute, Harvard University and the Massachusetts Institute of Technology.

View Press Release

LATEST

Sign up to receive updates from the CRISPR Collective

Related News

U.S. patent office issued third CRISPR patent to CVC; indicates it will issue a fourth
“Europe: Legal issues lead to invalidation of second Broad patent; significant reduction in scope of third Broad patent”
U.S. patent office indicates it will issue third CRISPR patent to UC
Read moreArrow-down